• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Alpha-N-acetylgalactosaminidase (NAGA)

ACP24036

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP24036 Target NameNAGA
Target SynonymsNAGA; Alpha-N-acetylgalactosaminidase; EC 3.2.1.49; Alpha-galactosidase BFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range18-411
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP17050
Background Information
  • Uniprot Id

    P17050

  • Target Species

    Human

  • Target Name

    NAGA

  • Target Full Name

    Alpha-N-acetylgalactosaminidase

  • Target Function

    Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. Required for the breakdown of glycolipids.

  • Target Involvement

    Schindler disease (SCHIND); Kanzaki disease (KANZD)

  • Target Subcellular Location

    Lysosome.

  • Target Protein Families

    Glycosyl hydrolase 27 family

  • Target Synonyms

    NAGA; Alpha-N-acetylgalactosaminidase; EC 3.2.1.49; Alpha-galactosidase B

  • Target Background

    NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, which cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Schindler disease types I and II (type II also known as Kanzaki disease).

Inquire Recombinant Human Alpha-N-acetylgalactosaminidase (NAGA) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification